Next Generation mucosal vaccines

Abera Bioscience is developing the next generation mucosal vaccines based on our proprietary vaccine delivery platform.

hexa-02 copy
Vaccine Platform Development at Abera

Novel Vaccine Platform

With the novel vaccine platform BERA, Abera can decorate Outer Membrane Vesicles (OMVs) with large amounts of antigen of one or more varieties. The OMVs enhances the immune response and antigen provides strong and broad protection.

Universal pneumococcal vaccine

Vaccine Pipeline

Abera develops a pipeline of mucosal vaccine candidates based on its proprietary technology. The lead candidate is a universal pneumococcal vaccine candidate given as a nasal spray now in preparation for clinical trials. Abera also develops vaccine technologies for pandemic preparedness.

Abera is taking OMV technology to the next level and use it as the basis for development of multiple vaccine candidates suitable for mucosal administration, like nasal spray administration. 

Abera combines novel technologies, known antigens and break-through improvements with over 30 years of microbiological experience to create innovative vaccines.

Abera Bioscience
Abera Bioscience

Abera is taking OMV technology to the next level and use it as the basis for development of multiple vaccine candidates suitable for mucosal administration, like nasal spray administration. 

Abera combines novel technologies, known antigens and break-through improvements with over 30 years of microbiological experience to create innovative vaccines.

hexa-03

NEWS

Artikel: Mukosala vacciner

Denna artikel är en fördjupning inom mukosala vacciner och en del i en serie fördjupningsartiklar från Abera Bioscience. Sammanfattning Vacciner är ett av de mest

Read More »

Abera is dedicated to the development of novel vaccines to save lives and increase health globally.

hexa-02 copy